|
1.
|
Neutel JM: Choosing among
renin-angiotensin system blockers for the management of
hypertension: From pharmacology to clinical efficacy. Curr Med Res
Opin. 26:213–222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Dahlöf B, Devereux RB, Kjeldsen SE, Julius
S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K,
Lederballe-Pedersen O, et al: LIFE Study Group: Cardiovascular
morbidity and mortality in the Losartan Intervention For Endpoint
reduction in hypertension study (LIFE): A randomised trial against
atenolol. Lancet. 359:995–1003. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Julius S, Kjeldsen SE, Weber M, Brunner
HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, et
al: VALUE Study Group: Outcomes in hypertensive patients at high
cardiovascular risk treated with regimens based on valsartan or
amlodipine: The VALUE randomised trial. Lancet. 363:2022–2231.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Lindholm LH, Ibsen H, Borch-Johnsen K,
Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U,
Fyhrquist F, et al: LIFE Study Group: Risk of new-onset diabetes in
the Losartan Intervention For Endpoint reduction in hypertension
study. J Hypertens. 20:1879–1886. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Clasen R, Schupp M, Foryst-Ludwig A,
Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T and
Kintscher U: PPARgamma-activating angiotensin type-1 receptor
blockers induce adiponectin. Hypertension. 46:137–143. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Higgins LS and Depaoli AM: Selective
peroxisome proliferator-activated receptor gamma (PPARgamma)
modulation as a strategy for safer therapeutic PPARgamma
activation. Am J Clin Nutr. 91:267S–272S. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Benson SC, Pershadsingh HA, Ho CI,
Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA and
Kurtz TW: Identification of telmisartan as a unique angiotensin II
receptor antagonist with selective PPARgamma-modulating activity.
Hypertension. 43:993–1002. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Schupp M, Janke J, Clasen R, Unger T and
Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome
proliferator-activated receptor-gamma activity. Circulation.
109:2054–2057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Henriksen EJ, Jacob S, Kinnick TR, Teachey
MK and Krekler M: Selective angiotensin II receptor antagonism
reduces insulin resistance in obese Zucker rats. Hypertension.
38:884–890. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Li GW and Pan XR: A new
insulin-sensitivity index for the population-based study. Zhonghua
Nei Ke Za Zhi. 32:656–660. 1993.(In Chinese). PubMed/NCBI
|
|
11.
|
Sridhar MG, Vinayagamoorthi R, Arul
Suyambunathan V, Bobby Z and Selvaraj N: Bitter gourd (Momordica
charantia) improves insulin sensitivity by increasing skeletal
muscle insulin-stimulated IRS-1 tyrosine phosphorylation in
high-fat-fed rats. Br J Nutr. 99:806–812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Allison DB, Paultre F, Maggio C, Mezzitis
N and Pi-Sunyer FX: The use of areas under curves in diabetes
research. Diabetes Care. 18:245–250. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Cheung A and Bryer-Ash M: Modified method
for the performance of glucose insulin clamp studies in conscious
rats. J Pharmacol Toxicol Methods. 31:215–220. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kump DS and Booth FW: Sustained rise in
triacylglycerol synthesis and increased epididymal fat mass when
rats cease voluntary wheel running. J Physiol. 565:911–925. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Matsuda M and DeFronzo RA: Insulin
sensitivity indices obtained from oral glucose tolerance testing:
Comparison with the euglycemic insulin clamp. Diabetes Care.
22:1462–1470. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Burnier M and Brunner HR: Angiotensin II
receptor antagonists. Lancet. 355:637–645. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Tuncer I, Ozbek H, Ugras S and Bayram I:
Anti-fibrogenic effects of captopril and candesartan cilexetil on
the hepatic fibrosis development in rat. The effect of AT1-R
blocker on the hepatic fibrosis. Exp Toxicol Pathol. 55:159–166.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Yusuf S, Pfeffer MA, Swedberg K, Granger
CB, Held P, McMurray JJ, Michelson EL, Olofsson B and Ostergren J:
CHARM Investigators and Committees: Effects of candesartan in
patients with chronic heart failure and preserved left-ventricular
ejection fraction: The CHARM-Preserved trial. Lancet. 362:777–781.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Granger CB, McMurray JJ, Yusuf S, Held P,
Michelson EL, Olofsson B, Ostergren J, Pfeffer MA and Swedberg K:
CHARM Investigators and Committees: Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular
systolic function intolerant to angiotensin-converting-enzyme
inhibitors: The CHARM-Alternative trial. Lancet. 362:772–776. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
McMurray JJ, Ostergren J, Swedberg K,
Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S and Pfeffer
MA: CHARM Investigators and Committees: Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular
systolic function taking angiotensin-converting-enzyme inhibitors:
The CHARM-Added trial. Lancet. 362:767–771. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Lithell H, Hansson L, Skoog I, Elmfeldt D,
Hofman A, Olofsson B, Trenkwalder P and Zanchetti A: SCOPE Study
Group: The Study on cognition and prognosis in the elderly (SCOPE):
Principal results of a randomized double-blind intervention trial.
J Hypertens. 21:875–886. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Grassi G, Seravalle G, Dell'Oro R, Trevano
FQ, Bombelli M, Scopelliti F, Facchini A and Mancia G: CROSS Study:
Comparative effects of candesartan and hydrochlorothiazide on blood
pressure, insulin sensitivity and sympathetic drive in obese
hypertensive individuals: Results of the CROSS study. J Hypertens.
21:1761–1769. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Lindholm LH, Persson M, Alaupovic P,
Carlberg B, Svensson A and Samuelsson O: Metabolic outcome during 1
year in newly detected hypertensives: Results of the
Antihypertensive Treatment and Lipid Profile in a North of Sweden
Efficacy evaluation (ALPINE study). J Hypertens. 21:1563–1574.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kinnick TR, Youngblood EB, O'Keefe MP,
Saengsirisuwan V, Teachey MK and Henriksen EJ: Modulation of
insulin resistance and hypertension by voluntary exercise training
in the TG(mREN2)27 rat. J Appl Physiol (1985). 93:805–812;
discussion 797. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Michalik L, Auwerx J, Berger JP,
Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T,
Lazar MA, O'Rahilly S, et al: International Union of Pharmacology.
LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev.
58:726–741. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Balakumar P, Rose M and Singh M: PPAR
ligands: Are they potential agents for cardiovascular disorders?
Pharmacology. 80:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kersten S, Desvergne B and Wahli W: Roles
of PPARs in health and disease. Nature. 405:421–424. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Spiegelman BM: PPAR-gamma: Adipogenic
regulator and thiazolidinedione receptor. Diabetes. 47:507–514.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Kurtz TW: Treating the metabolic syndrome:
Telmisartan as a peroxisome proliferator-activated receptor-gamma
activator. Acta Diabetol. 42(Suppl 1): S9–S16. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Morsing P, Adler G, Brandt-Eliasson U,
Karp L, Ohlson K, Renberg L, Sjöquist PO and Abrahamsson T:
Mechanistic differences of various AT1-receptor blockers in
isolated vessels of different origin. Hypertension. 33:1406–1413.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y
and Shin EK: Anti-inflammatory and metabolic effects of candesartan
in hypertensive patients. Int J Cardiol. 108:96–100. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ
and Burrell MA: The adipocyte: A model for integration of endocrine
and metabolic signaling in energy metabolism regulation. Am J
Physiol Endocrinol Metab. 280:E827–E847. 2001.PubMed/NCBI
|
|
33.
|
Banerjee RR and Lazar MA: Resistin:
Molecular history and prognosis. J Mol Med (Berl). 81:218–226.
2003.PubMed/NCBI
|
|
34.
|
Goossens GH, Blaak EE and van Baak MA:
Possible involvement of the adipose tissue renin-angiotensin system
in the pathophysiology of obesity and obesity-related disorders.
Obes Rev. 4:43–55. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Engeli S, Böhnke J, Gorzelniak K, Janke J,
Schling P, Bader M, Luft FC and Sharma AM: Weight loss and the
renin-angiotensin-aldosterone system. Hypertension. 45:356–362.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Motley ED, Eguchi K, Gardner C, Hicks AL,
Reynolds CM, Frank GD, Mifune M, Ohba M and Eguchi S:
Insulin-induced Akt activation is inhibited by angiotensin II in
the vasculature through protein kinase C-alpha. Hypertension.
41:775–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Furuhashi M, Ura N, Takizawa H, Yoshida D,
Moniwa N, Murakami H, Higashiura K and Shimamoto K: Blockade of the
renin-angiotensin system decreases adipocyte size with improvement
in insulin sensitivity. J Hypertens. 22:1977–1982. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
de Gasparo M, Catt KJ, Inagami T, Wright
JW and Unger T: International Union of Pharmacology. XXIII. The
angiotensin II receptors. Pharmacol Rev. 52:415–472.
2000.PubMed/NCBI
|
|
39.
|
Hao GH, Niu XL, Gao DF, Wei J and Wang NP:
Agonists at PPAR-gamma suppress angiotensin II-induced production
of plasminogen activator inhibitor-1 and extracellular matrix in
rat cardiac fibroblasts. Br J Pharmacol. 153:1409–1419. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Sugawara A, Takeuchi K, Uruno A, Ikeda Y,
Arima S, Kudo M, Sato K, Taniyama Y and Ito S: Transcriptional
suppression of type 1 angiotensin II receptor gene expression by
peroxisome proliferator-activated receptor-gamma in vascular smooth
muscle cells. Endocrinology. 142:3125–3134. 2001. View Article : Google Scholar : PubMed/NCBI
|
